Physician profile
Nathaniel Runne
NPI 1609255272
$1,018.46
in general payments reported to CMS, 2019-2025
15 companies · $242 in 2025
The $242 reported for 2025 was more than what 80% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.74 · 2020: $68.65 · 2021: $213 · 2022: $134 · 2023: $165 · 2024: $160 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $212.81 | 2021-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $181.82 | 2022-2025 | Lifevest |
| Pfizer INC. | $155.57 | 2019-2024 | |
| La Jolla Pharmaceutical Company | $79.30 | 2023-2025 | Xerava, Xacduro, Zevtera |
| Merck Sharp & Dohme LLC | $65.47 | 2020-2024 | Dificid |
| Tetraphase Pharmaceuticals, INC. | $54.76 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $39.60 | 2024-2025 | |
| Abbvie INC. | $38.47 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $37.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $36.37 | 2023 | |
| Ucb, INC. | $32.53 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $25.56 | 2022 | |
| Allergan, INC. | $23.93 | 2019 | |
| Nestle Healthcare Nutrition INC. | $19.10 | 2023 | |
| Gilead Sciences, INC. | $15.73 | 2023 | Veklury |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Runne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.